Release date: 5 September 2017
Promoter – Financial Intermediary
HUVEPHARMA INTERNATIONAL BVLocation
Description
The project consists of the construction of new manufacturing facilities, as well as financing of the promoter's research, development and innovation (RDI) activities.
Objectives
The EIB loan will be supporting the capacity expansion of a mid-cap company in Bulgaria.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 125 million
Total cost (Approximate amount)
EUR 212 million
Environmental aspects
The project falls under Annex II of EIA Directive 2011/92/EU (implementation of an industrial facility for the production of pharmaceutical products). Full environmental details will be assessed during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU directives on procurement.
Status
Signed - 22/12/2017
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).